Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997–4126. https://doi.org/10.1093/eurheartj/ehac262.

PubMed  Google Scholar 

Gómez-Mesa JE, Márquez-Murillo M, Figueiredo M, Berni A, Jerez AM, Núñez-Ayala E, Romero A. Inter-American Society of Cardiology (CIFACAH-ELECTROSIAC) and Latin-American Heart Rhythm Society (LAHRS): multidisciplinary review on the appropriate use of implantable cardiodefibrillator in heart failure with reduced ejection fraction. J Interv Cardiac Electrophysiol: An Int J Arrhythmias Pacing. 2023;66(5):1211–29. https://doi.org/10.1007/s10840-022-01425-4.

Google Scholar 

Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, McMurray JJV. Declining risk of sudden death in heart failure. New England J Med. 2017;377(1):41–51. https://doi.org/10.1056/NEJMoa1609758.

Google Scholar 

Gierula J, Paton MF, Witte KK. Advances in cardiac resynchronization and implantable cardioverter/defibrillator therapy: Medtronic Cobalt and Crome. Future Cardiol. 2021;17(4):609–18. https://doi.org/10.2217/fca-2020-0117.

CAS  PubMed  Google Scholar 

Ågesen FN, Lynge TH, Blanche P, Banner J, Prescott E, Jabbari R, Tfelt-Hansen J. Temporal trends and sex differences in sudden cardiac death in the Copenhagen City Heart Study. Heart (British Cardiac Society). 2021;107(16):1303–9. https://doi.org/10.1136/heartjnl-2020-318881.

PubMed  Google Scholar 

Briongos-Figuero S, García-Alberola A, Rubio J, Segura JM, Rodríguez A, Peinado R, UMBRELLA Investigators. Long-term outcomes among a nationwide cohort of patients using an implantable cardioverter-defibrillator: UMBRELLA Study Final Results. J Am Heart Assoc. 2021;10(1):e018108. https://doi.org/10.1161/JAHA.120.018108.

PubMed  Google Scholar 

Merchant FM, Hoskins MH, Benser ME, Roberts G, Bastek AN, Knezevic A, El-Chami MF. Time course of subsequent shocks after initial implantable cardioverter-defibrillator discharge and implications for driving restrictions. JAMA Cardiology. 2016;1(2):181. https://doi.org/10.1001/jamacardio.2015.0386.

PubMed  Google Scholar 

Almehmadi F, Porta-Sánchez A, Ha ACT, Fischer HD, Wang X, Austin PC, Nanthakumar K. Mortality implications of appropriate implantable cardioverter defibrillator therapy in secondary prevention patients contrasting mortality in primary prevention patients from a prospective population-based registry. J Am Heart Assoc. 2017;6(8):e006220. https://doi.org/10.1161/JAHA.117.006220.

PubMed  PubMed Central  Google Scholar 

da Silva KR, Costa R, Rodrigues CG, Schasechter A, Nobre MC, Passman R, Mark DB. Quality of life in patients with implantable cardioverter–defibrillator: systematic review of randomized controlled trials. Eur J Cardiovasc Nurs. 2018;17(3):196–206. https://doi.org/10.1177/1474515117739619.

PubMed  Google Scholar 

Weber D, Koller M, Theuns D, Yap S, Kühne M, Sticherling C, Schaer B. Predicting defibrillator benefit in patients with cardiac resynchronization therapy: a competing risk study. Heart Rhythm. 2019;16(7):1057–64. https://doi.org/10.1016/j.hrthm.2019.01.033.

PubMed  Google Scholar 

Santangeli P, Pelargonio G, Dello Russo A, Casella M, Bisceglia C, Bartoletti S, Natale A. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. Heart Rhythm. 2010;7(7):876–82. https://doi.org/10.1016/j.hrthm.2010.03.042.

PubMed  Google Scholar 

Zareba W, Moss AJ, Jackson Hall W, Wilber DJ, Ruskin JN, McNitt S, MADITII Investigators. Clinical course and implantable cardioverter defibrillator therapy in postinfarction women with severe left ventricular dysfunction. J Cardiovasc Electrophysiol. 2005;16(12):1265–70. https://doi.org/10.1111/j.1540-8167.2005.00224.x.

PubMed  Google Scholar 

Konstantino Y, Shafat T, Novack V, Novack L, Amit G. Incidence of implantable cardioverter defibrillator therapy and mortality in primary and secondary prevention of sudden cardiac death. Israel Med Assoc J: IMAJ. 2015;17(12):760–3.

Google Scholar 

Lee DS, Hardy J, Yee R, Healey JS, Birnie D, Simpson CS, Tu JV. Clinical risk stratification for primary prevention implantable cardioverter defibrillators. Circulation Heart Failure. 2015;8(5):927–37. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002414.

PubMed  PubMed Central  Google Scholar 

Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–867. https://doi.org/10.1093/eurheartj/ehv316.

PubMed  Google Scholar 

Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, Al-Khatib SM, Almendral J, Document Reviewers. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace: Eur Pacing, Arrhythmias, Cardiac Electrophysiol. 2016;18(2):159–83. https://doi.org/10.1093/europace/euv411.

Google Scholar 

Varma N, Jones P, Wold N, Cronin E, Stein K. How well do results from randomized clinical trials and/or recommendations for implantable cardioverter-defibrillator programming diffuse into clinical practice? Translation assessed in a national cohort of patients with implantable cardioverter-defibrillators ( ALTITUDE ). J Am Heart Assoc. 2019;8(3): e007392. https://doi.org/10.1161/JAHA.117.007392.

PubMed  PubMed Central  Google Scholar 

A healthy lifestyle - WHO recommendations. (n.d.). Retrieved April 8, 2023, from https://www.who.int/europe/news-room/fact-sheets/item/a-healthy-lifestyle---who-recommendations

Auricchio A, Hudnall JH, Schloss EJ, Sterns LD, Kurita T, Meijer A, Rogers T. Inappropriate shocks in single-chamber and subcutaneous implantable cardioverter-defibrillators a systematic review and meta-analysis. Europace Eur Pacing, Arrhythmias, Cardiac Electrophysiol. 2017;19(12):1973–80. https://doi.org/10.1093/europace/euw415.

Google Scholar 

Dichtl W, De Sousa J, Rubin Lopez JM, Campo EG, Gutleben K-J, Poezevara Y, Probst V. Low rates of inappropriate shocks in contemporary real-world implantable cardioverter defibrillator patients: the CARAT observational study. Europace: Europ Pacing, Arrhythmias, Cardiac Electrophysiol. 2023;25(9):euad186. https://doi.org/10.1093/europace/euad186.

Google Scholar 

Klein RC, Raitt MH, Wilkoff BL, Beckman KJ, Coromilas J, Wyse DG, Greene HL. Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Cardiovasc Electrophysiol. 2003;14(9):940–8. https://doi.org/10.1046/j.1540-8167.2003.01554.x.

PubMed  Google Scholar 

Bardy GH, Boineau R, Johnson G, Davidson-Ray LD, Ip JH. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. New England J Med. 2005;13:225.

Google Scholar 

Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110(25):3760–5. https://doi.org/10.1161/01.CIR.0000150390.04704.B7.

PubMed  Google Scholar 

Dougherty CM, Hunziker J. Predictors of implantable cardioverter defibrillator (ICD) shocks during the first year. J Cardiovasc Nurs. 2009;24(1):21–30. https://doi.org/10.1097/01.JCN.0000317473.42801.a8.

PubMed  PubMed Central  Google Scholar 

van Welsenes GH, van Rees JB, Borleffs CJW, Cannegieter SC, Bax JJ, van Erven L, Schalij MJ. Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiol. 2011;13(3):389–94. https://doi.org/10.1093/europace/euq494.

Google Scholar 

Weeke P, Johansen JB, Jorgensen OD, Nielsen JC, Moller M, Videbaek R, Jacobsen PK. Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter-defibrillators for primary prevention: data from the Danish ICD Register. Europace. 2013;15(8):1150–7. https://doi.org/10.1093/europace/eut017.

PubMed  Google Scholar 

Ruwald MH, Ruwald A-C, Johansen JB, Gislason G, Lindhardt TB, Nielsen JC, Philbert BT. Temporal incidence of appropriate and inappropriate therapy and mortality in secondary prevention ICD patients by cardiac diagnosis. JACC Clin Electrophysiol. 2021;7(6):781–92. https://doi.org/10.1016/j.jacep.2020.11.005.

PubMed  Google Scholar 

Teerawongsakul P, Ananwattanasuk T, Chokesuwattanaskul R, Shah M, Lathkar-Pradhan S, Barham W, Tanawuttiwat T. Programming of implantable cardioverter defibrillators for primary prevention outcomes at centers with high vs. low concordance with guidelines. J Interv Cardiac Electrophysiol. 2023;66(6):1359–66. https://doi.org/10.1007/s10840-022-01431-6.

Google Scholar 

Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P, Moss AJ. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II. J Am College Cardiol. 2008;51(14):1357–65. https://doi.org/10.1016/j.jacc.2007.09.073.

Google Scholar 

Sabbag A, Suleiman M, Laish-Farkash A, Samania N, Kazatsker M, Goldenberg I, Beinart R. Contemporary rates of appropriate shock therapy in patients who receive implantable device therapy in a real-world setting: from the Israeli ICD Registry. Heart Rhythm. 2015;12(12):2426–33. https://doi.org/10.1016/j.hrthm.2015.08.020.

PubMed  Google Scholar 

Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Page RL. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. J Am College Cardiol. 2018;72(14):e91–220. https://doi.org/10.1016/j.jacc.2017.10.054.

Google Scholar 

Myerburg RJ, Mitrani R, Interian A, Castellanos A. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation. 1998;97(15):1514–21. https://doi.org/10.1161/01.cir.97.15.1514.

CAS  PubMed  Google Scholar 

Zhou Y, Zhao S, Chen K, Hua W, Su Y, Chen S, Zhang S. Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients. BMC Cardiovasc Disorders. 2019;19(1):230. https://doi.org/10.1186/s12872-019-1218-9.

Google Scholar 

Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Bardy GH. Prognostic importance of defibrillator shocks in patients with heart failure. New England J Med. 2008;359(10):1009–17. https://doi.org/10.1056/NEJMoa071098.

CAS  Google Scholar 

Powell BD, Saxon LA, Boehmer JP, Day JD, Gilliam FR, Heidenreich PA, Hayes DL. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. J Am College Cardiol. 2013;62(18):1674–9. https://doi.org/10.1016/j.jacc.2013.04.083.

Google Scholar 

Weng W, Sapp J, Doucette S, MacIntyre C, Gray C, Gardner M, Parkash R. Benefit of implantable cardioverter-defibrillator generator replacement in a primary prevention population-based cohort. JACC Clin Electrophysiol. 2017;3(10):1180–9. https://doi.org/10.1016/j.jacep.2017.03.004.

PubMed